Earnings summaries and quarterly performance for CARLISLE COMPANIES.
Executive leadership at CARLISLE COMPANIES.
D. Christian Koch
Chair, President and Chief Executive Officer
Christopher B. Gaskill
Vice President and General Counsel
Frank J. Ready
President, Carlisle Weatherproofing Technologies
Jason Taylor
President, Carlisle Construction Materials
Kevin P. Zdimal
Vice President and Chief Financial Officer
Scott C. Selbach
Executive Vice President, Government Relations and Secretary
Board of directors at CARLISLE COMPANIES.
Research analysts who have asked questions during CARLISLE COMPANIES earnings calls.
Bryan Blair
Oppenheimer
6 questions for CSL
Garik Shmois
Loop Capital Markets
6 questions for CSL
Susan Maklari
Goldman Sachs Group Inc.
6 questions for CSL
Keith Hughes
Truist Financial Corporation
4 questions for CSL
Timothy Wojs
Robert W. Baird & Co.
4 questions for CSL
Adam Baumgarten
Zelman & Associates
3 questions for CSL
David Macgregor
Longbow Research
3 questions for CSL
Joseph Nolan
Longbow Research
3 questions for CSL
Tomohiko Sano
JPMorgan Chase & Co.
3 questions for CSL
Saree Boroditsky
Jefferies
2 questions for CSL
Tim Wojs
Robert W. Baird & Co. Incorporated
2 questions for CSL
Recent press releases and 8-K filings for CSL.
- Carlisle (CSL) reported Q3 2025 revenue of $1.3 billion, an increase of 1% year-over-year, and adjusted EPS of $5.61.
- The company revised its full-year 2025 guidance to anticipate flat revenue year-over-year and an adjusted EBITDA margin decline of approximately 250 basis points.
- Performance was driven by the strength of the underlying CCM business, particularly strong reroofing demand, which was partially offset by ongoing challenges in residential and non-residential new construction markets.
- Carlisle maintained its commitment to capital deployment, repurchasing 800,000 shares for $300 million in Q3, raising its dividend by 10%, and increasing its full-year share buyback target to $1.3 billion.
- The company also issued $1 billion of debt in Q3, maintaining a net debt to EBITDA ratio of 1.4 times as of September 30, 2025.
- CSL reported Q3 2025 revenue of $1,347 million, a 1% year-over-year increase, with Adjusted EPS of $5.61 and an Adjusted EBITDA Margin of 25.9%.
- The company returned $347 million to shareholders in Q3 2025 through dividends and share repurchases, and increased its share buyback target for the year to $1.3 billion.
- CSL revised its full-year 2025 outlook to project flat revenue year-over-year and an Adjusted EBITDA margin compression of 250 basis points from 2024.
- Performance was influenced by M&A contributions and strong commercial re-roofing, which helped to offset lower volumes from soft new construction and residential R&R markets.
- Carlisle Companies Incorporated reported Q3 2025 revenue of $1.3 billion, a 1% year-over-year increase, though organic revenue declined 2%.
- Adjusted EPS was $5.61, down 3% from the prior year, with an adjusted EBITDA margin of 25.9%, a 170 basis point decrease.
- The company revised its full-year 2025 guidance, now expecting consolidated revenue to be flat year-over-year and adjusted EBITDA margin to decline approximately 250 basis points.
- Carlisle increased its full-year 2025 share buyback target to $1.3 billion and announced a 10% dividend increase, its 49th consecutive annual increase.
- Carlisle Companies reported Q3 2025 revenue of $1.3 billion, a 1% year-over-year increase, and adjusted EPS of $5.61, a 3% decrease.
- The Carlisle Construction Materials (CCM) segment showed resilience with strong reroofing demand, maintaining an adjusted EBITDA margin of over 30%, while the Carlisle Weatherproofing Technologies (CWT) segment continued to be negatively impacted by soft new construction and residential markets.
- The company repurchased 800,000 shares for $300 million in Q3 2025, raised its dividend by 10%, and increased its full-year 2025 share buyback target to $1.3 billion.
- Carlisle updated its full-year 2025 outlook, expecting consolidated revenue to be flat year-over-year and adjusted EBITDA margins to decline approximately 250 basis points compared to 2024.
- CSL Vifor and Travere Therapeutics support the recently published KDIGO 2025 clinical practice guidelines for IgA Nephropathy (IgAN), which define diagnostic criteria, treatment goals, and treatment approaches for the disease.
- The updated guidelines suggest treatment with FILSPARI® (sparsentan), a Dual Endothelin Angiotensin Receptor Antagonist (DEARA), as a potential first-line approach for IgAN-induced nephron loss, noting its proven efficacy compared to optimized RASi in clinical trials.
- The PROTECT Study, a Phase 3 trial, showed that FILSPARI achieved a 49.8% mean reduction in proteinuria from baseline after 36 weeks, significantly outperforming the 15.1% reduction seen in irbesartan-treated patients.
- FILSPARI is a non-immunosuppressive therapy approved in the U.S. and Europe, and has been launched in Germany, Austria, Switzerland, Luxembourg, and the UK.
Quarterly earnings call transcripts for CARLISLE COMPANIES.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more